Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABEO

ABEO - Abeona Therapeutics Inc Stock Price, Fair Value and News

6.70USD-0.05 (-0.74%)Market Closed
Watchlist

Market Summary

USD6.70-0.05
Market Closed
-0.74%

ABEO Alerts

  • Point72 Asset Management, L.P. reported owning 6.4% of ABEO [2024-02-14]
  • 1 major insider buys recently.

ABEO Stock Price

View Fullscreen

ABEO RSI Chart

ABEO Valuation

Market Cap

166.0M

Price/Earnings (Trailing)

-3.71

Price/Sales (Trailing)

110.55

Price/Free Cashflow

-3.94

ABEO Price/Sales (Trailing)

ABEO Profitability

Return on Equity

-202.91%

Return on Assets

-67.67%

Free Cashflow Yield

-25.37%

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

250%

Rev. Growth (Qtr)

-100%

ABEO Earnings

Earnings (TTM)

-44.7M

Earnings Growth (Yr)

-83.96%

Earnings Growth (Qtr)

28.93%

Breaking Down ABEO Revenue

Last 7 days

13.1%

Last 30 days

33.5%

Last 90 days

67.3%

Trailing 12 Months

182.7%

How does ABEO drawdown profile look like?

ABEO Financial Health

Current Ratio

6.81

ABEO Investor Care

Shares Dilution (1Y)

44.23%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20222.6M2.2M1.8M1.4M
20218.3M6.5M4.8M3.0M
202000010.0M
20190000
20186.9M7.5M9.0M9.3M
20171.0M843.0K878.0K837.0K
20161.3M1.4M1.5M1.1M
2015358.9K672.8K986.6K1.3M
20141.0M806.0K853.0K45.0K
20133.8M3.6M2.9M2.0M
20123.5M4.1M3.9M4.4M
20112.0M1.9M1.9M1.8M
20100002.0M

Tracking the Latest Insider Buys and Sells of Abeona Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 06, 2024
seshadri vishwas
bought
87,800
4.39
20,000
chief executive officer
Jan 17, 2024
alvino mark
sold
-36,199
5.11
-7,084
-
Oct 16, 2023
seshadri vishwas
sold (taxes)
-749
4.14
-181
chief executive officer
Sep 29, 2023
seshadri vishwas
sold (taxes)
-52,229
3.93
-13,290
chief executive officer
Sep 29, 2023
o'malley brendan m.
sold (taxes)
-25,769
3.93
-6,557
svp, general counsel
Sep 29, 2023
vazzano joseph walter
sold (taxes)
-24,483
3.93
-6,230
chief financial officer
Sep 27, 2023
silverstein christine berni
sold
-24,721
3.9054
-6,330
-
Sep 27, 2023
charles faith l.
sold
-40,923
4.9128
-8,330
-
Sep 27, 2023
amoroso michael
sold
-21,542
3.9111
-5,508
-
Sep 27, 2023
alland leila
sold
-28,269
3.9014
-7,246
-

1–10 of 50

Which funds bought or sold ABEO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-49,000
-
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-54.28
-714,000
850,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
204,844
204,844
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
95.86
12,873,800
22,547,500
0.67%
Feb 14, 2024
VANGUARD GROUP INC
added
46.25
2,346,810
5,516,670
-%
Feb 14, 2024
Point72 Asset Management, L.P.
reduced
-35.58
-1,160,350
3,811,960
0.01%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
456,511
456,511
-%
Feb 14, 2024
Royal Bank of Canada
added
14,314
5,000
5,000
-%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
unchanged
-
2,600,000
16,282,500
0.03%

1–10 of 42

Are Funds Buying or Selling ABEO?

Are funds buying ABEO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABEO
No. of Funds

Unveiling Abeona Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
point72 asset management, l.p.
6.4%
1,649,740
SC 13G/A
Feb 14, 2024
armistice capital, llc
4.99%
1,301,114
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
4.2%
1,086,956
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
9.9%
2,499,781
SC 13G/A
Feb 12, 2024
flynn james e
3.39%
869,565
SC 13G/A
Jan 10, 2024
integrated core strategies (us) llc
5.5%
1,363,572
SC 13G/A
Dec 04, 2023
integrated core strategies (us) llc
5.4%
1,334,725
SC 13G
Jul 06, 2023
adage capital partners gp, l.l.c.
15.32%
3,249,994
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
7.4%
1,150,648
SC 13G/A
Feb 14, 2023
armistice capital, llc
6.44%
1,106,000
SC 13G

Recent SEC filings of Abeona Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
4
Insider Trading
Jan 22, 2024
4
Insider Trading
Jan 10, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Dec 04, 2023
SC 13G
Major Ownership Report

Peers (Alternatives to Abeona Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Abeona Therapeutics Inc News

Latest updates
MarketBeat20 Feb 202404:16 am
Seeking Alpha19 Feb 202401:27 pm
Yahoo Finance15 Feb 202410:52 am
InvestorsObserver07 Feb 202404:26 pm

Abeona Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-100.0%-3,5001,78468.00-1,0003468771,4081,9382,4693,0007,0006,0695,1384,2073,2752,3441,4134821,709
Costs and Expenses------------------23,97619,05418,49218,625
Operating Expenses-19.4%11,33414,05412,03813,0049,3809,00820,93749,65214,87213,71514,59717,48013,24812,48148,21116,41117,64923,97619,05418,49218,625
  S&GA Expenses-17.2%4,1565,0213,9975,6823,8903,4604,2244,3755,8165,1826,2807,3974,4325,5386,4124,7344,7005,6125,6597,6314,970
  R&D Expenses-16.1%7,1488,5238,0416,2725,4906,65810,54512,8129,0568,5338,3179,2437,9696,1096,8189,60510,91716,30711,7379,47013,150
Interest Expenses1.9%10510310117815720020153.006831,5001,4201,3881,327800600----2.003.00
Net Income28.9%-11,836-16,654-9,107-7,121-6,434-4,097-22,044-46,683-7,044-15,207-16,002-15,828-7,237-13,010-48,159-16,431-17,372-23,924-18,555-17,479-16,419
Net Income Margin-13.7%-31.63*-27.80*-18.92*-28.07*-43.78*-36.19*-34.94*-28.31*-11.39*-8.35*-6.31*-8.42*-9.14*--------
Free Cashflow44.1%-5,790-10,360-11,918-14,034-6,793-9,013-13,790-33,505-10,736-11,546-14,029-1,643-10,973--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets23.4%66.0054.0053.0064.0039.0045.0055.0080.00119131141151159164175223143159166174161
  Current Assets30.0%57.0044.0043.0053.0025.0030.0039.0056.0068.0079.0089.0098.0010510911913250.0065.0072.0089.00115
    Cash Equivalents-24.3%5.006.005.0014.006.006.0020.0033.0044.0027.0014.0013.008.0015.0040.0012948.0043.0026.0019.0034.00
  Net PPE-10.9%4.004.005.006.007.007.008.0012.0010.0010.0011.0011.0012.0013.0013.0013.0014.0014.0010.009.009.00
  Goodwill---------32.0032.0032.0032.0032.0032.0032.0032.0032.0032.0032.0032.0032.00
Liabilities-0.4%44.0044.0035.0037.0023.0025.0024.0037.0039.0047.0047.0049.0044.0043.0043.0045.0047.0052.0048.0040.0010.00
  Current Liabilities-10.9%8.009.007.008.0013.0014.0012.0017.0026.0042.0041.0042.0039.0038.0037.0039.0020.0026.0021.0020.0010.00
Shareholder's Equity135.8%22.009.0019.0027.0012.0014.0021.0042.0080.0084.0094.0010311512113217896.00107118134150
  Retained Earnings-1.6%-732-721-704-695688682-676-655-608-601-586-570-554-547-534-486-470-452-428-410-392
  Additional Paid-In Capital3.4%755730723722701694697697688685680672669668666664566559546544542
Shares Outstanding15.1%25.0021.0018.0018.006.006.006.006.004.004.004.004.004.00--------
Float------29.00---137---204---131---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations44.4%-5,746-10,328-11,700-14,009-6,791-9,013-13,687-30,257-10,334-11,489-13,585-1,610-10,702-9,475-13,232-14,246-18,254-15,242-15,078-16,967-9,040
  Share Based Compensation68.0%1,5579277708336327248622,0012,5372,4281,9503,06689.001471,2562,61166.001,6782,1032,4432,499
Cashflow From Investing-459.7%-18,7435,2112,211-25,2901,649-1,3981,0757,99926,76321,9249,3765,7824,584-18,209-75,871-94619,22818,92022,7742,119-10,430
Cashflow From Financing247.2%22,9766,618-4.0042,7664,189--16,3311732,4795,8783.00---96,5274,34013,00728.00-1.003,079

ABEO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
License and other revenues$ 3,500$ 1,346
Expenses:    
Royalties301,605350
Research and development7,1485,49023,71222,693
General and administrative4,1563,89013,17411,574
Impairment of licensed technology1,355
Loss/(gain) on right-of-use lease assets(1,065)1,561
Impairment of construction-in-progress1,792
Total expenses11,3349,38037,42639,325
Loss from operations(11,334)(9,380)(33,926)(37,979)
Interest income593721,374103
Interest expense(105)(157)(309)(558)
Change in fair value of warrant liabilities(1,101)3,050(7,465)5,995
Other income (expense)111(19)2,729(136)
Net loss(11,836)(6,434)(37,597)(32,575)
Deemed dividends related to Series A and Series B Convertible Redeemable Preferred Stock(3,782)
Net loss attributable to Common Shareholders$ (11,836)$ (6,434)$ (37,597)$ (36,357)
Loss per common share - basic$ (0.48)$ (1.00)$ (1.89)$ (6.05)
Loss per common share - diluted$ (0.48)$ (1.00)$ (1.89)$ (6.05)
Weighted average number of common shares outstanding - basic24,797,5646,421,24519,942,6136,009,902
Weighted average number of common shares outstanding - diluted24,797,5646,421,24519,942,6136,009,902
Other comprehensive income (loss):    
Change in unrealized gains (losses) related to available-for-sale debt securities$ (33)$ (4)$ 1$ (11)
Foreign currency translation adjustments29(6)29(6)
Comprehensive loss$ (11,840)$ (6,444)$ (37,567)$ (36,374)

ABEO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 4,712$ 14,217
Short-term investments49,04237,932
Restricted cash338338
Other receivables2,209188
Prepaid expenses and other current assets963424
Total current assets57,26453,099
Property and equipment, net3,9995,741
Right-of-use lease assets4,6855,331
Other assets13943
Total assets66,08764,214
Current liabilities:  
Accounts payable2,5921,811
Accrued expenses3,9723,991
Current portion of operating lease liability1,6491,773
Other current liabilities199204
Total current liabilities8,4127,779
Long-term operating lease liabilities4,0435,854
Warrant liabilities27,12219,657
Total liabilities44,04937,453
Commitments and contingencies
Stockholders’ equity:  
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
Common stock - $0.01 par value; authorized 200,000,000 shares; 24,713,908 and 17,719,720 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively247177
Additional paid-in capital754,823722,049
Accumulated deficit(732,933)(695,336)
Accumulated other comprehensive loss(99)(129)
Total stockholders’ equity22,03826,761
Total liabilities and stockholders’ equity66,08764,214
Related Party [Member]  
Current liabilities:  
Payable to licensor$ 4,472$ 4,163
ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
 CEO
 WEBSITEwww.abeonatherapeutics.com
 EMPLOYEES57

Abeona Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Abeona Therapeutics Inc? What does ABEO stand for in stocks?

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abeona Therapeutics Inc (ABEO)?

As of Thu Feb 22 2024, market cap of Abeona Therapeutics Inc is 165.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers. The fair value of Abeona Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abeona Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abeona Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

What is Abeona Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ABEO's PE ratio (Price to Earnings) is -3.71 and Price to Sales (PS) ratio is 110.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abeona Therapeutics Inc's stock?

In the past 10 years, Abeona Therapeutics Inc has provided -0.082 (multiply by 100 for percentage) rate of return.